MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New strategy aims to stop transplant complications in kids with blood cancer
Disease control Recruiting nowThis study tests a new way to prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers who receive a donor stem cell transplant. Researchers remove a specific type of immune cell (naive T cells) from the donor cells before transplant to red…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:25 UTC
-
Engineered stem cell graft aims to improve transplant success in blood cancers
Disease control Recruiting nowThis early-phase study tests a new way to prepare donor stem cells (called Orca-Q) for transplant in people with certain blood cancers like leukemia. The goal is to see if this engineered graft is safe and helps the body accept the new cells without serious side effects. About 30…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 17, 2026 04:25 UTC
-
New hope for hard-to-treat blood cancers: experimental therapy aims to tame dangerous transplant side effects
Disease control Recruiting nowThis early-stage trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in people with advanced blood cancers who receive a stem cell transplant from a partially matched donor. The main goal is to see if this approach red…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
New hope for babies with aggressive leukemia: targeted therapy trial launches
Disease control Recruiting nowThis study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants will take part, and the tr…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New combo therapy aims to boost leukemia treatment
Disease control Recruiting nowThis study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will take…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New stem cell approach offers hope for blood cancer patients
Disease control Recruiting nowThis study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New combo therapy targets Hard-to-Treat leukemias
Disease control Recruiting nowThis study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with certain types of acute leukemia that have come back or not responded to treatment. The trial includes about 52 participants aged 12 and older with specific genetic changes in their le…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Radioactive antibody targets leukemia before transplant
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk acute leukemias or myelodysplastic syndrome. The antibody seeks out and delivers radiation to cancer cells while sparing healthy cells. The goal is to find …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Immune cell boost after transplant may stop leukemia return in tough cases
Disease control Recruiting nowThis study tests whether giving special immune cells (NK cells) before and after a stem cell transplant can help prevent leukemia from coming back in children and young adults (ages 0–25) with acute leukemia that is hard to treat or has leftover disease. The NK cells are grown in…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New combo therapy aims to stop relapse in tough blood cancers
Disease control Recruiting nowThis study tests a new treatment for adults with aggressive blood cancers like acute myeloid leukemia (AML) that are hard to cure. Patients receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and total body radiation, followed by a stem cell transplant from a h…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New cell therapy aims to improve stem cell transplant outcomes for blood cancer patients
Disease control Recruiting nowThis study tests a personalized cell therapy called Orca-T for 80 adults with acute myeloid leukemia or myelodysplastic syndrome. Participants receive a stem cell transplant with specially processed donor cells designed to reduce complications like graft-versus-host disease. The …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New cord blood transplant approach targets tough blood cancers
Disease control Recruiting nowThis study tests a refined cord blood transplant method for people with high-risk blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to prepare the body, then drugs after to prevent rejection. The goal is to improve sur…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New gene therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New pill shows promise for leukemia patients out of options
Disease control Recruiting nowThis early-stage trial tests an experimental pill called MRX-2843 in teens and adults whose acute leukemia has returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 50 participants will take the pill daily in 2…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
New hope for leukemia patients: targeted drug shows promise
Disease control Recruiting nowThis study tests a new drug called revumenib in people with certain types of leukemia that have come back or not responded to other treatments. The goal is to find the best dose and see if it can help control the disease. About 447 adults with specific genetic changes (MLL/KMT2A …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
New targeted therapy could boost survival for High-Risk leukemia patients
Disease control Recruiting nowThis study tests whether adding a targeted drug called inotuzumab ozogamicin to standard chemotherapy and immunotherapy can improve outcomes for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). About 5,951 participants will receive either the …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
New hope for kids with aggressive leukemia: trial tests powerful drug combos
Disease control Recruiting nowThis study is testing whether adding one of two targeted drugs, dasatinib or venetoclax, to standard chemotherapy can improve outcomes for children and young adults with newly diagnosed T-cell leukemia or lymphoma. The main goal is to see if more patients achieve a deep, early re…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Apr 15, 2026 16:16 UTC
-
New study aims to match kids with blood cancer to the best treatment faster
Knowledge-focused Recruiting nowThis study enrolls children and teens (ages 1-18) newly diagnosed with acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. The main goal is to collect enough information about each patient's cancer to determine their risk of the disease return…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE4 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated May 17, 2026 04:14 UTC
-
New screening trial aims to match kids with relapsed leukemia to better treatments
Knowledge-focused Recruiting nowThis study screens children and young adults (up to age 22) whose leukemia has returned or is difficult to treat. By testing their blood and bone marrow, doctors look for specific genetic markers to match them with the most promising experimental treatments. The goal is to improv…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Knowledge-focused
Last updated May 04, 2026 16:30 UTC